FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896961006> ?p ?o ?g. }

• W2896961006 endingPage "S63" @default.
• W2896961006 startingPage "S62" @default.
• W2896961006 abstract "The programmed death ligand-1 (PD-L1) and programmed death-1 (PD1) signaling axis is exploited by cancer cells as a mechanism to evade the host’s immune surveillance. The expression of PD-L1 has been shown to be prognostic in many cancer types and expression status has been used in consideration of checkpoint inhibitor immunotherapy treatment. However, there are very limited and conflicting data on the prognostic impact of PD-L1 in patients with anal cancer. The objectives of this retrospective study were to measure expression of PD-L1 and CD8 in patients with anal cancer treated chemoradiation (CRT), and to correlate tumor expression with overall survival (OS). A total of 102 patients with anal cancer treated with primary CRT at two tertiary care cancer centers between 2000 and 2013, with available pre-treatment tumor, were included. Tissue microarrays from tumor specimens were stained for PD-L1 and CD8. PD-L1 expression in tumor and in stroma was quantified using HALO image analysis software, and the results were interpreted using novel quantitative methods comparing average pixel intensity of the tissue sample normalized to reference cell lines. The density of CD8 cells within the tumor was interpreted by a specialist pathologist semi-quantitatively, using a 0-4 scoring system. Kaplan-Meier analysis with log rank was used to determine significance in association between tumor markers and OS. Cox multivariate analysis (forward stepwise Wald) was used to explore independent predictors of OS. Of the 102 patients, 65 (64%) had sufficient tumor sample available for full analysis. There were no differences in baseline characteristics between tested and not tested cases. Mean follow up was 14.1 years; the female:male ratio was 2.5:1. Most patients had T2 disease; the majority were squamous histology (88%). We analyzed commonly used PD-L1 expression levels from the literature, and determined that the 5% cut-point was most strongly prognostic for OS. Approximately half the patients had tumoral PD-L1 expression ≥5%. Patients with tumoral PD-L1 ≥5% had better OS vs those with lower expression, HR=0.29 (CI 0.10-0.78), p=0.009; 10 years OS: 84% for PD-L1 ≥5% vs. 46% for PD-L1 <5%. On univariate analysis, OS was associated with PD-L1 status, as well as T stage, N stage, ECOG status and gender. On multivariate analysis, PD-L1 ≥5% remained statistically significant for better OS, HR=0.35 (CI 0.12-0.99), p=0.047. 33 of 65 (51%) of tumors had high CD8 levels (3 or 4). There was no association between CD8 status and OS; further stratifying PD-L1 high patients by CD8 did not improve the prognostic impact vs PD-L1 status alone. This is the first study reporting significant association of PD-L1 expression with OS in patients with anal cancer treated with CRT. PD-L1 status warrants consideration in the prognostication of patients with anal cancer. Future studies are required to determine the benefit of alternative treatment strategies based on PD-L1 status." @default.
• W2896961006 created "2018-10-26" @default.
• W2896961006 creator A5009354470 @default.
• W2896961006 creator A5010097733 @default.
• W2896961006 creator A5010557687 @default.
• W2896961006 creator A5022868286 @default.
• W2896961006 creator A5033670325 @default.
• W2896961006 creator A5037302810 @default.
• W2896961006 creator A5040191407 @default.
• W2896961006 creator A5048003275 @default.
• W2896961006 creator A5051886441 @default.
• W2896961006 creator A5053375225 @default.
• W2896961006 creator A5079909589 @default.
• W2896961006 creator A5086449500 @default.
• W2896961006 date "2018-11-01" @default.
• W2896961006 modified "2023-10-18" @default.
• W2896961006 title "The Prognostic Impact of PD-L1 and CD8 Expression in Anal Cancer Patients Treated with Chemoradiotherapy" @default.
• W2896961006 doi "https://doi.org/10.1016/j.ijrobp.2018.06.175" @default.
• W2896961006 hasPublicationYear "2018" @default.
• W2896961006 type Work @default.
• W2896961006 sameAs 2896961006 @default.
• W2896961006 citedByCount "1" @default.
• W2896961006 countsByYear W28969610062021 @default.
• W2896961006 crossrefType "journal-article" @default.
• W2896961006 hasAuthorship W2896961006A5009354470 @default.
• W2896961006 hasAuthorship W2896961006A5010097733 @default.
• W2896961006 hasAuthorship W2896961006A5010557687 @default.
• W2896961006 hasAuthorship W2896961006A5022868286 @default.
• W2896961006 hasAuthorship W2896961006A5033670325 @default.
• W2896961006 hasAuthorship W2896961006A5037302810 @default.
• W2896961006 hasAuthorship W2896961006A5040191407 @default.
• W2896961006 hasAuthorship W2896961006A5048003275 @default.
• W2896961006 hasAuthorship W2896961006A5051886441 @default.
• W2896961006 hasAuthorship W2896961006A5053375225 @default.
• W2896961006 hasAuthorship W2896961006A5079909589 @default.
• W2896961006 hasAuthorship W2896961006A5086449500 @default.
• W2896961006 hasConcept C10515644 @default.
• W2896961006 hasConcept C121608353 @default.
• W2896961006 hasConcept C126322002 @default.
• W2896961006 hasConcept C142724271 @default.
• W2896961006 hasConcept C143998085 @default.
• W2896961006 hasConcept C167672396 @default.
• W2896961006 hasConcept C193270364 @default.
• W2896961006 hasConcept C203014093 @default.
• W2896961006 hasConcept C204232928 @default.
• W2896961006 hasConcept C2777701055 @default.
• W2896961006 hasConcept C2778424827 @default.
• W2896961006 hasConcept C2779840525 @default.
• W2896961006 hasConcept C2781053074 @default.
• W2896961006 hasConcept C38180746 @default.
• W2896961006 hasConcept C50382708 @default.
• W2896961006 hasConcept C71924100 @default.
• W2896961006 hasConcept C8891405 @default.
• W2896961006 hasConceptScore W2896961006C10515644 @default.
• W2896961006 hasConceptScore W2896961006C121608353 @default.
• W2896961006 hasConceptScore W2896961006C126322002 @default.
• W2896961006 hasConceptScore W2896961006C142724271 @default.
• W2896961006 hasConceptScore W2896961006C143998085 @default.
• W2896961006 hasConceptScore W2896961006C167672396 @default.
• W2896961006 hasConceptScore W2896961006C193270364 @default.
• W2896961006 hasConceptScore W2896961006C203014093 @default.
• W2896961006 hasConceptScore W2896961006C204232928 @default.
• W2896961006 hasConceptScore W2896961006C2777701055 @default.
• W2896961006 hasConceptScore W2896961006C2778424827 @default.
• W2896961006 hasConceptScore W2896961006C2779840525 @default.
• W2896961006 hasConceptScore W2896961006C2781053074 @default.
• W2896961006 hasConceptScore W2896961006C38180746 @default.
• W2896961006 hasConceptScore W2896961006C50382708 @default.
• W2896961006 hasConceptScore W2896961006C71924100 @default.
• W2896961006 hasConceptScore W2896961006C8891405 @default.
• W2896961006 hasIssue "3" @default.
• W2896961006 hasLocation W28969610061 @default.
• W2896961006 hasOpenAccess W2896961006 @default.
• W2896961006 hasPrimaryLocation W28969610061 @default.
• W2896961006 hasRelatedWork W2084432955 @default.
• W2896961006 hasRelatedWork W2150205536 @default.
• W2896961006 hasRelatedWork W2361700749 @default.
• W2896961006 hasRelatedWork W2367310955 @default.
• W2896961006 hasRelatedWork W2569537049 @default.
• W2896961006 hasRelatedWork W3194098699 @default.
• W2896961006 hasRelatedWork W3208148470 @default.
• W2896961006 hasRelatedWork W4200608643 @default.
• W2896961006 hasRelatedWork W4285032905 @default.
• W2896961006 hasRelatedWork W4285038142 @default.
• W2896961006 hasVolume "102" @default.
• W2896961006 isParatext "false" @default.
• W2896961006 isRetracted "false" @default.
• W2896961006 magId "2896961006" @default.
• W2896961006 workType "article" @default.